Literature DB >> 28401327

Pulmonary embolism response teams.

Maya Serhal1, Ihab S Haddadin2, Gustavo A Heresi3, Deborah A Hornacek1, Mehdi H Shishehbor1, John R Bartholomew4.   

Abstract

Pulmonary embolism (PE) is a common thrombotic event that is variable in its presentation. Depending on the patients' risk for mortality, guidelines provide several treatment strategies including thrombolysis, catheter-directed therapies, pulmonary embolectomy, anticoagulation, and inferior vena cava filters. However, there is considerable disagreement between guidelines regarding the optimal treatment strategy for patients, particularly for those with intermediate-risk PE. In order to provide rapid and individualized care, PE response teams (PERT) have been developed. These teams consist of members from different specialties with a particular interest in PE, varying technical skills, and clinical experience, thereby allowing for a multidisciplinary approach. PERT allows for consensus decision making, and for rapid intervention in patients whose conditions worsen. In this review, we provide an overview of treatment guidelines for PE, and of results from recent clinical trials involving patients with submassive PE. In addition, we discuss an outline of our approach and use of PERT.

Entities:  

Keywords:  Pulmonary embolism; Pulmonary embolism response team (PERT); Rapid response team; Thrombolytic; Venous thromboembolism

Mesh:

Substances:

Year:  2017        PMID: 28401327     DOI: 10.1007/s11239-017-1498-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study.

Authors:  Gregory Piazza; Benjamin Hohlfelder; Michael R Jaff; Kenneth Ouriel; Tod C Engelhardt; Keith M Sterling; Noah J Jones; John C Gurley; Rohit Bhatheja; Robert J Kennedy; Nilesh Goswami; Kannan Natarajan; John Rundback; Immad R Sadiq; Stephen K Liu; Narinder Bhalla; M Laiq Raja; Barry S Weinstock; Jacob Cynamon; Fakhir F Elmasri; Mark J Garcia; Mark Kumar; Juan Ayerdi; Peter Soukas; William Kuo; Ping-Yu Liu; Samuel Z Goldhaber
Journal:  JACC Cardiovasc Interv       Date:  2015-08-24       Impact factor: 11.195

3.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial).

Authors:  Mohsen Sharifi; Curt Bay; Laura Skrocki; Farnoosh Rahimi; Mahshid Mehdipour
Journal:  Am J Cardiol       Date:  2012-10-24       Impact factor: 2.778

5.  Transforming and simplifying the treatment of pulmonary embolism: "safe dose" thrombolysis plus new oral anticoagulants.

Authors:  Mohsen Sharifi; Zoltan Vajo; Wilbur Freeman; Curt Bay; Mirali Sharifi; Frederic Schwartz
Journal:  Lung       Date:  2015-03-07       Impact factor: 2.584

6.  A comparison of the original and simplified Pulmonary Embolism Severity Index.

Authors:  Carmen Venetz; David Jiménez; Marie Mean; Drahomir Aujesky
Journal:  Thromb Haemost       Date:  2011-06-28       Impact factor: 5.249

7.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report.

Authors:  Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores
Journal:  Chest       Date:  2016-01-07       Impact factor: 9.410

8.  Derivation and validation of a prognostic model for pulmonary embolism.

Authors:  Drahomir Aujesky; D Scott Obrosky; Roslyn A Stone; Thomas E Auble; Arnaud Perrier; Jacques Cornuz; Pierre-Marie Roy; Michael J Fine
Journal:  Am J Respir Crit Care Med       Date:  2005-07-14       Impact factor: 21.405

9.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

10.  Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.

Authors:  Sam Schulman; Ajay K Kakkar; Samuel Z Goldhaber; Sebastian Schellong; Henry Eriksson; Patrick Mismetti; Anita Vedel Christiansen; Jeffrey Friedman; Florence Le Maulf; Nuala Peter; Clive Kearon
Journal:  Circulation       Date:  2013-12-16       Impact factor: 29.690

View more
  4 in total

1.  A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic.

Authors:  Jamal H Mahar; Ihab Haddadin; Divyajot Sadana; Abishek Gadre; Natalie Evans; Deborah Hornacek; Natalia Fendrikova Mahlay; Marcelo Gomes; Douglas Joseph; Maya Serhal; Michael Zhen-Yu Tong; Seth R Bauer; Michael Militello; Bernard Silver; Mehdi Shishehbor; John R Bartholomew; Gustavo A Heresi
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

2.  Pharmacists as members of an interdisciplinary pulmonary embolism response team.

Authors:  Christine M Groth; Nicole M Acquisto; Colin Wright; Mark Marinescu; Scott McNitt; Ilan Goldenberg; Scott J Cameron
Journal:  J Am Coll Clin Pharm       Date:  2021-11-22

3.  Pulmonary Embolism: Contemporary Medical Management and Future Perspectives.

Authors:  Stefano Barco; Stavros V Konstantinides
Journal:  Ann Vasc Dis       Date:  2018-09-25

4.  Role of Pulmonary Embolism Response Team in patients with intermediate- and high-risk pulmonary embolism: a concise review and preliminary experience from China.

Authors:  Ying Liang; Shao-Ping Nie; Xiao Wang; Ashley Thomas; Elizabeth Thompson; Guan-Qi Zhao; Jing Han; Jing Wang; Mark J D Griffiths
Journal:  J Geriatr Cardiol       Date:  2020-08       Impact factor: 3.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.